期刊
CURRENT HEMATOLOGIC MALIGNANCY REPORTS
卷 10, 期 4, 页码 395-404出版社
CURRENT MEDICINE GROUP
DOI: 10.1007/s11899-015-0283-0
关键词
Multiple myeloma; Cellular immunotherapy; Monoclonal antibodies; Allogeneic transplantation; Vaccine therapy; Idiotype vaccine
资金
- Ludwig Institute for Cancer Research
Multiple myeloma is a disorder of terminally differentiated plasma cells, characterized by immune dysfunction, deregulated signaling within the bone marrow stromal compartment, and a microenvironment that fosters immunosuppression. Immunomodulatory techniques, such as allogeneic hematopoietic stem cell transplant (allo-HCT) and donor lymphocyte infusion (DLI), demonstrate long-term disease control via manipulation of the immunologic milieu. However, allo-HCT is associated with numerous toxicities including infectious complications and graft versus host effect and is not suitable for many patients. Novel agents and cellular-based therapies aim to restore the balance of humoral and adaptive immunity without the morbidity of allo-HCT and DLI. In the following review, we will summarize the use of immunomodulatory techniques in multiple myeloma, including monoclonal antibodies, vaccine therapy, checkpoint inhibitors, autologous T cells, and engineered T cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据